ZA95679B - Products containing G-CSF and TNF binding protein - Google Patents

Products containing G-CSF and TNF binding protein

Info

Publication number
ZA95679B
ZA95679B ZA95679A ZA95679A ZA95679B ZA 95679 B ZA95679 B ZA 95679B ZA 95679 A ZA95679 A ZA 95679A ZA 95679 A ZA95679 A ZA 95679A ZA 95679 B ZA95679 B ZA 95679B
Authority
ZA
South Africa
Prior art keywords
csf
binding protein
pharmaceutically acceptable
tnf binding
acceptable salt
Prior art date
Application number
ZA95679A
Other languages
English (en)
Inventor
Gottfried Alber
Peter Angehrn
Original Assignee
Hoffman La Roche A G F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffman La Roche A G F filed Critical Hoffman La Roche A G F
Publication of ZA95679B publication Critical patent/ZA95679B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA95679A 1994-02-04 1995-01-27 Products containing G-CSF and TNF binding protein ZA95679B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810059 1994-02-04

Publications (1)

Publication Number Publication Date
ZA95679B true ZA95679B (en) 1995-08-08

Family

ID=8218199

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA95679A ZA95679B (en) 1994-02-04 1995-01-27 Products containing G-CSF and TNF binding protein

Country Status (16)

Country Link
US (2) US5776895A (xx)
EP (1) EP0668077B1 (xx)
JP (1) JP2765807B2 (xx)
CN (1) CN1097468C (xx)
AT (1) ATE202709T1 (xx)
AU (1) AU693833B2 (xx)
BR (1) BR9500436A (xx)
CA (1) CA2139385C (xx)
DE (1) DE69521536T2 (xx)
DK (1) DK0668077T3 (xx)
ES (1) ES2160643T3 (xx)
GR (1) GR3036774T3 (xx)
NZ (1) NZ270422A (xx)
PT (1) PT668077E (xx)
RU (1) RU2139084C1 (xx)
ZA (1) ZA95679B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
EP1028626A4 (en) * 1997-11-07 2001-05-16 Uab Research Foundation METHOD FOR INCREASING GENE EXPRESSION
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
EP2311485A1 (en) * 1998-07-30 2011-04-20 The Government of the United States of America, as represented by the Secretary of Health and Human Services Thymosin beta 4 promotes wound repair
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2003210806A1 (en) * 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
DE602004013557D1 (de) 2003-02-28 2008-06-19 Ares Trading Sa FLÜSSIGE FORMULIERUNGEN DES TUMORNEKROSEFRAKTOR-BINDUNGSPROTEINs TBP-1
CN101679511A (zh) * 2007-06-06 2010-03-24 杜门蒂斯有限公司 多肽、抗体可变域和拮抗剂
JP5702150B2 (ja) 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されているレプチンポリペプチドおよびそれらの使用
UA103774C2 (uk) * 2008-07-23 2013-11-25 Амбркс, Інк. Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
SG10202001779UA (en) 2015-01-20 2020-04-29 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
AU2018348138A1 (en) * 2017-10-11 2020-04-23 Ambrx, Inc. Porcine G-CSF variants and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP1018552B1 (en) * 1985-08-23 2006-07-05 Kirin-Amgen, Inc. Production of pluripotent granulocyte colony-stimulating factor
US4985241A (en) * 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
JP2864434B2 (ja) * 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
PT639079E (pt) * 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
ES2197150T3 (es) * 1992-05-05 2004-01-01 Aeres Biomedical Limited Anticuerpos contra p-selectina y sus utilizaciones.

Also Published As

Publication number Publication date
EP0668077A1 (en) 1995-08-23
DE69521536T2 (de) 2002-04-18
CN1097468C (zh) 2003-01-01
RU2139084C1 (ru) 1999-10-10
JP2765807B2 (ja) 1998-06-18
AU693833B2 (en) 1998-07-09
AU1146295A (en) 1995-08-17
DE69521536D1 (de) 2001-08-09
EP0668077B1 (en) 2001-07-04
BR9500436A (pt) 1995-10-17
RU95101385A (ru) 1996-12-27
CA2139385C (en) 2001-12-25
ES2160643T3 (es) 2001-11-16
DK0668077T3 (da) 2001-10-08
US5776895A (en) 1998-07-07
NZ270422A (en) 1996-06-25
GR3036774T3 (en) 2002-01-31
CA2139385A1 (en) 1995-08-05
ATE202709T1 (de) 2001-07-15
PT668077E (pt) 2001-12-28
US5750503A (en) 1998-05-12
JPH07258300A (ja) 1995-10-09
CN1111158A (zh) 1995-11-08

Similar Documents

Publication Publication Date Title
AU693833B2 (en) Products containing G-CSF and TNF binding protein
BE2018C038I2 (xx)
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
PL309594A1 (en) Apllication of rilusole in treating parkinson disease and parkinsonian syndromes
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
EP0734723A4 (en) THERAPEUTIC COMPOSITION USEFUL FOR TREATING HYPERPARATHYROIDIA OF A PATIENT ON ARTIFICIAL DIALYSIS
EP0347899A3 (en) Pharmaceutical compositions on egg shell basis and their preparation and use
EP1006793A4 (en) COMPOSITIONS FOR TREATING ARRHYTHMIA AND METHODS OF TREATMENT
HK124595A (en) Anthocyanidins for the treatment of ophthalmic diseases
MY104124A (en) Therapeutic compounds.
EP0343671A3 (en) Pharmaceutical composition for the treatment of skin wounds
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
NZ268039A (en) Use of efaroxan in treating parkinson's disease
IL126158A0 (en) Method for treating substance abuse
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
CA2147749A1 (en) Therapeutic agent for diseases of periodontal tissue
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
RU98114855A (ru) Использование 1-энантиомер центхромана для получения фармацевтической композиции для лечения и профилактики рака молочной железы
MX9603833A (es) Tratamiento mejorado del cancer con temozolomida.